Peter J. O’Dwyer

Generating author description...

All published works

Action	Title	Year	Authors
+ PDF Chat	The New NCI Precision Medicine Trials	2023	Lyndsay N. Harris Charles D. Blanke Harry P. Erba James M. Ford Robert J. Gray Michael LeBlanc Siwen Hu‐Lieskovan Mark R. Litzow Selina M. Luger Funda Meric‐Bernstam
+	The NCI-MATCH trial: lessons for precision oncology	2023	Peter J. O’Dwyer Robert J. Gray Keith T. Flaherty Alice Chen Shuli Li Victoria Wang Lisa M. McShane David R. Patton James V. Tricoli P. Mickey Williams
+	Phase II Trials	2004	Keith T. Flaherty Peter J. O’Dwyer
+	Phase I Clinical Trial Design in Cancer Drug Development	2000	Elizabeth A. Eisenhauer Peter J. O’Dwyer Michaele C. Christian Jeffrey S. Humphrey
+	Phase II Clinical Trials in Oncology	1997	Khater Christine Paul B. Laub James M. Gallo André Rogatko Peter J. O’Dwyer
+	Patient treatment on a compassionate basis: Documentation of high adverse drug reaction rate	1992	Brian Leyland‐Jones Barbara Davies K Clagett-Carr DeWayne Shoemaker Donald E. Macfarlane Clarence L. Fortner Peter J. O’Dwyer Gisele Sarosy B J Foster Honggu Chun

Common Coauthors

Coauthor	Papers Together
Lyndsay N. Harris	2
David Patton	2
Lisa M. McShane	2
James H. Doroshow	2
Robert J. Gray	2
Keith T. Flaherty	2
Richard F. Little	2
Khater Christine	1
Larry Rubinstein	1
Donald E. Macfarlane	1
Gisele Sarosy	1
Charles D. Blanke	1
Larissa A. Korde	1
Honggu Chun	1
Michael LeBlanc	1
Donna M. Marinucci	1
Carlos L. Arteaga	1
Alice Chen	1
Mark J. Routbort	1
Harry P. Erba	1
Helen X. Chen	1
K Clagett-Carr	1
Barbara A. Conley	1
A. John Iafrate	1
James M. Gallo	1
P B Laub	1
David Sims	1
Clarence L. Fortner	1
Siwen Hu‐Lieskovan	1
Katerina Politi	1
Brian Leyland‐Jones	1
Carmen J. Allegra	1
Brent Coffey	1
Funda Meric‐Bernstam	1
Laura M. Yee	1
James V. Tricoli	1
Stanley R. Hamilton	1
Jeffrey A. Moscow	1
S. Percy Ivy	1
Naoko Takebe	1
Edith P. Mitchell	1
Barbara Davies	1
Mark R. Litzow	1
DeWayne Shoemaker	1
André Rogatko	1
P. Mickey Williams	1
Shuli Li	1
Elizabeth A. Eisenhauer	1
Victoria Wang	1
B J Foster	1

Commonly Cited References

Action	Title	Year	Authors	# of times referenced
+	Bayesian Individualization of Pharmacokinetics: Simple Implementation and Comparison with Non-Bayesian Methods	1982	Lewis B. Sheiner Stuart L. Beal	2
+	Population Pharmacokinetics	1986	B. Whiting Andrew W. Kelman Joachim Grevel	2
+	Clinical drug development: an analysis of phase II trials, 1970-1985.	1987	Silvia Marsoni Daniel F. Hoth Richard Simon B Leyland-Jones Marina De Rosa R. Wittes	2
+	Potential roles for preclinical pharmacology in phase I clinical trials.	1986	Jerry M. Collins Daniel S. Zaharko Robert L. Dedrick B A Chabner	2
+ PDF Chat	The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design	2020	Keith T. Flaherty Robert J. Gray Alice Chen Shuli Li David R. Patton Stanley R. Hamilton P. Mickey Williams Edith P. Mitchell A. John Iafrate Jeffrey Sklar	2
+	Population Pharmacokinetics/Dynamics*	1992	Lewis B. Sheiner Thomas M. Ludden	2
+	Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development.	1992	Carl C. Peck William H. Barr Leslie Z. Benet Jerry M. Collins Robert E. Desjardins Daniel E. Furst John G. Harter Gerhard Levy Thomas M. Ludden John H. Rodman	2
+	Cancer phase I clinical trials: efficient dose escalation with overdose control	1998	James S. Babb André Rogatko Shelemyahu Zacks	1
+	Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer	1990	John O’Quigley Margaret S. Pepe Lloyd D. Fisher	1
+	Calibrated phase II clinical trials in oncology	1986	Jay Herson Stephen K. Carter	1
+	Phase I trial design: Are new methodologies being put into practice?	1996	Susan Dent E. Eisenhauer	1
+ PDF Chat	Workshop on phase I study design	1996	Susan G. Arbuck	1
+	Planned versus attained design in phase II clinical trials	1992	Stephanie Green Steve Dahlberg	1
+ PDF Chat	Accelerated Titration Designs for Phase I Clinical Trials in Oncology	1997	Richard Simon Larry Rubinstein Susan G. Arbuck Michaele C. Christian Boris Freidlin Jerry M. Collins	1
+	Some practical improvements in the continual reassessment method for phase I studies	1995	Steven N. Goodman Marianna Zahurak Steven Piantadosi	1
+	Incorporating historical control data in planning phase II clinical trials	1990	Peter F. Thall Richard Simon	1
+	Estimating the Probability of Toxicity at the Recommended Dose Following a Phase I Clinical Trial in Cancer	1992	John O’Quigley	1
+	Randomized phase II clinical trials.	1985	Richard Simon R. Wittes Susan S. Ellenberg	1
+	Population kinetics and conditional assessment of the optimal dosage regimen using the P-PHARM software package.	1994	Roberto Goméni Gilles Pineau France Mentré	1
+	Pharmacokinetically guided dose escalation phase I clinical trials. commentary and proposed guidelines.	1987	Pharmacokinetics Eortc	1
+	Pharmacokinetically guided dose escalation in phase I clinical trials. Commentary and proposed guidelines	1987		1
+	Delivering precision oncology to patients with cancer	2022	Joaquı́n Mateo Lotte Steuten Philippe Aftimos Fabrice André D. M. Davies Elena Garralda Jan Geißler Don Husereau Iciar Martinez-Lopez Nicola Normanno	1
+	Limited sampling models for amonafide (NSC 308847) pharmacokinetics.	1988	Mark J. Ratain Alfred E. Staubus Richard L. Schilsky Louis Malspeis	1
+	A decade of progress in statistical methodology for clinical trials	1991	Richard Simon	1
+	One-Sample Multiple Testing Procedure for Phase II Clinical Trials	1982	Thomas R. Fleming	1
+	Pharmacologically Guided Phase I Clinical Trials Based Upon Preclinical Drug Development	1990	Jerry M. Collins Charles K. Grieshaber Bruce A. Chabner	1
+	Creatinine Clearance: Bedside Estimate	1973	Roger W. Jelliffe	1
+	A comparative phase II clinical trials procedure for choosing the best of three treatments	1991	Christopher R. Palmer	1